Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896825 | 0.86 | HTR2A (0.44) | PLA2G2AKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL18326403 | 0.83 | KDM4E (0.40) | PLA2G2AKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL16896944 | 0.82 | GRIN1 (0.39) | PLA2G2AKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL16906006 | 0.82 | BRD4 (0.41) | PLA2G2AGRIN1GRIN2BNOX4BRD4 | |
| SCHEMBL20547367 | 0.81 | KMT2A (0.54) | PLA2G2AKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL16896821 | 0.80 | SCN9A (0.38) | PLA2G2AKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL20373762 | 0.80 | KDM4E (0.37) | PLA2G2AKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL16896777 | 0.79 | GRIN1 (0.44) | GRIN1GRIN2BPDE5ABRD4 | |
| SCHEMBL16896904 | 0.79 | GRIN1 (0.39) | PLA2G2AGRIN1GRIN2BNOX4BRD4 | |
| SCHEMBL16896924 | 0.79 | GRIN1 (0.39) | PLA2G2AGRIN1GRIN2BNOX4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-11-29 | — | — | US | disclosed |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2018-09-18 | — | — | US | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| EP-3092227-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | PLA2G2A 2463/4885KMT2A 1208/4885KDM4E 2070/4885 |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | PLA2G2A 2463/4885KMT2A 1208/4885KDM4E 2070/4885 |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | PLA2G2A 2463/4885KMT2A 1208/4885KDM4E 2070/4885 |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | PLA2G2A 2463/4885KMT2A 1208/4885KDM4E 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.